C. Gorrini, I. S. Harris, and T. W. Mak, Modulation of oxidative stress as an anticancer strategy, Nat. Rev. Drug Discov, vol.12, issue.12, pp.931-947, 2013.

D. Trachootham, J. Alexandre, and P. Huang, Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?, Nat. Rev. Drug Discov, vol.8, issue.7, pp.579-591, 2009.

L. Chaiswing, W. H. St-clair, and D. K. St-clair, Redox paradox: a novel approach to therapeutics-resistant cancer, Antioxid Redox Signal, vol.29, issue.13, pp.1237-1272, 2018.

J. Du, J. J. Cullen, and G. R. Buettner, Ascorbic acid: chemistry, biology and the treatment of cancer, Biochim. Biophys. Acta, vol.1826, issue.2, pp.443-457, 2012.

A. J. Michels and B. Frei, Myths, artifacts, and fatal flaws: identifying limitations and opportunities in vitamin C research, Nutrients, vol.5, issue.12, pp.5161-5192, 2013.

Q. Chen, M. G. Espey, A. Y. Sun, J. H. Lee, M. C. Krishna et al., Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo, Proc. Natl. Acad. Sci. U.S.A, vol.104, issue.21, pp.8749-8754, 2007.

Q. Chen, M. G. Espey, A. Y. Sun, C. Pooput, K. L. Kirk et al., Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice, Proc. Natl. Acad. Sci. U.S.A, vol.105, issue.32, pp.11105-11109, 2008.

M. Levine, M. G. Espey, and Q. Chen, Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment, Free Radic, Biol. Med, vol.47, issue.1, pp.27-29, 2009.

K. E. Brandt, K. C. Falls, J. D. Schoenfeld, S. N. Rodman, Z. Gu et al., Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells, Redox Biol, vol.14, pp.82-87, 2018.

J. Yun, E. Mullarky, C. Lu, K. N. Bosch, A. Kavalier et al., Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH, Science, vol.350, issue.6266, pp.1391-1396, 2015.

C. M. Doskey, V. Buranasudja, B. A. Wagner, J. G. Wilkes, J. Du et al., Tumor cells have decreased ability to metabolize H 2 O 2 : implications for pharmacological ascorbate in cancer therapy, Redox Biol, vol.10, pp.274-284, 2016.

S. W. Hong, S. H. Lee, J. H. Moon, J. J. Hwang, D. E. Kim et al., SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment, Oncogene, vol.32, issue.12, pp.1508-1517, 2013.

C. Wohlrab, E. Phillips, and G. U. Dachs, Vitamin C transporters in cancer: current understanding and gaps in knowledge, Front Oncol, vol.7, p.74, 2017.

C. Wang, H. Lv, W. Yang, T. Li, T. Fang et al., SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts, Cancer Lett, vol.398, pp.1-11, 2017.

J. D. Schoenfeld, Z. A. Sibenaller, K. A. Mapuskar, B. A. Wagner, K. L. Cramer-morales et al., O 2 ?-and H 2 O 2 -mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate, Cancer Cell, vol.32, issue.2, p.268, 2017.

J. D. Schoenfeld, Z. A. Sibenaller, K. A. Mapuskar, M. D. Bradley, B. A. Wagner et al., Redox active metals and H 2 O 2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models, Redox Biol, vol.14, pp.417-422, 2018.

H. Pelicano, D. Carney, and P. Huang, ROS stress in cancer cells and therapeutic implications, vol.7, pp.97-110, 2004.

M. Uetaki, S. Tabata, F. Nakasuka, T. Soga, and M. Tomita, Metabolomic alterations in human cancer cells by vitamin C-induced oxidative stress, Sci. Rep, vol.5, p.13896, 2015.

Y. Ma, J. Chapman, M. Levine, K. Polireddy, J. Drisko et al., High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy, Sci. Transl. Med, vol.6, issue.222, pp.222-218, 2014.

J. Du, J. A. Cieslak-3rd, J. L. Welsh, Z. A. Sibenaller, B. G. Allen et al., Pharmacological ascorbate radiosensitizes pancreatic cancer, Cancer Res, vol.75, issue.16, pp.3314-3326, 2015.

J. Du, S. M. Martin, M. Levine, B. A. Wagner, G. R. Buettner et al., Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer, Clin. Cancer Res, vol.16, issue.2, pp.509-520, 2010.

X. Wei, Y. Xu, F. F. Xu, L. Chaiswing, D. Schnell et al., RelB expression determines the differential effects of ascorbic acid in normal and cancer cells, Cancer Res, vol.77, issue.6, pp.1345-1356, 2017.

K. Polireddy, R. Dong, G. Reed, J. Yu, P. Chen et al., High dose parenteral ascorbate inhibited pancreatic cancer growth and metastasis: mechanisms and a phase I/IIa study, Sci. Rep, vol.7, issue.1, p.17188, 2017.

T. He, E. Hatem, L. Vernis, M. Lei, and M. E. Huang, PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug, J. Exp. Clin. Cancer Res, vol.34, p.152, 2015.

P. Liu, H. Zhang, H. Wang, and Y. Xia, Identification of redox-sensitive cysteines in the Arabidopsis proteome using OxiTRAQ, a quantitative redox proteomics method, Proteomics, vol.14, issue.6, pp.750-762, 2014.

Y. Perez-riverol, A. Csordas, J. Bai, M. Bernal-llinares, S. Hewapathirana et al., The PRIDE database and related tools and resources in 2019: improving support for quantification data, Nucleic Acids Res, vol.47, issue.D1, pp.442-450, 2019.

D. Graindorge, S. Martineau, C. Machon, P. Arnoux, J. Guitton et al., Singlet oxygen-mediated oxidation during UVA radiation alters the dynamic of genomic DNA replication, PLoS One, vol.10, issue.10, p.140645, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01264850

E. Hatem, S. Azzi, N. E. Banna, T. He, A. Heneman-masurel et al., Auranofin/vitamin C: a novel drug combination targeting triple-negative breast cancer, J Natl Cancer Inst, vol.111, issue.6, pp.597-608, 2019.

A. J. Meyer and T. P. Dick, Fluorescent protein-based redox probes, Antioxid Redox Signal, vol.13, issue.5, pp.621-650, 2010.

V. V. Belousov, A. F. Fradkov, K. A. Lukyanov, D. B. Staroverov, K. S. Shakhbazov et al., Genetically encoded fluorescent indicator for intracellular hydrogen peroxide, Nat. Methods, vol.3, issue.4, pp.281-286, 2006.

Y. M. Go and D. P. Jones, The redox proteome, J. Biol. Chem, vol.288, issue.37, pp.26512-26520, 2013.

Y. M. Go, J. D. Chandler, and D. P. Jones, The cysteine proteome, Free Radic, Biol. Med, vol.84, pp.227-245, 2015.

O. Aguilera, M. Munoz-sagastibelza, B. Torrejon, A. Borrero-palacios, L. Puerto-nevado et al., Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer, Oncotarget, vol.7, issue.30, pp.47954-47965, 2016.

W. C. Reinhold, M. Sunshine, H. Liu, S. Varma, K. W. Kohn et al., CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set, Cancer Res, vol.72, issue.14, pp.3499-3511, 2012.

U. T. Shankavaram, S. Varma, D. Kane, M. Sunshine, K. K. Chary et al., CellMiner: a relational database and query tool for the NCI-60 cancer cell lines, BMC Genomics, vol.10, p.277, 2009.

T. He, A. Banach-latapy, L. Vernis, M. Dardalhon, R. Chanet et al., Peroxiredoxin 1 knockdown potentiates beta-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals, Carcinogenesis, vol.34, issue.4, pp.760-769, 2013.

M. Bajor, A. O. Zych, A. Graczyk-jarzynka, A. Muchowicz, M. Firczuk et al., Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents, Br J Cancer, vol.119, issue.7, pp.873-884, 2018.

Q. Chen, M. G. Espey, M. C. Krishna, J. B. Mitchell, C. P. Corpe et al., Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues, Proc. Natl. Acad. Sci. U.S.A, vol.102, issue.38, pp.13604-13609, 2005.

M. Levine, S. J. Padayatty, and M. G. Espey, Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries, Adv Nutr, vol.2, issue.2, pp.78-88, 2011.

E. De-nadal, G. Ammerer, and F. Posas, Controlling gene expression in response to stress, Nat. Rev. Genet, vol.12, issue.12, pp.833-845, 2011.

B. Liu and S. B. Qian, Translational reprogramming in cellular stress response, Wiley Interdiscip Rev RNA, vol.5, issue.3, pp.301-315, 2014.

D. Silvera, S. C. Formenti, and R. J. Schneider, Translational control in cancer, vol.10, issue.4, pp.254-266, 2010.

L. M. Lindqvist, I. Vikstrom, J. M. Chambers, K. Mcarthur, M. Anderson et al., Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor, Cell Death Dis, issue.3, p.409, 2012.

M. Bhat, N. Robichaud, L. Hulea, N. Sonenberg, J. Pelletier et al., Targeting the translation machinery in cancer, Nat. Rev. Drug Discov, vol.14, issue.4, pp.261-278, 2015.

X. Ren, S. M. Santhosh, L. Coppo, F. T. Ogata, J. Lu et al., The combination of ascorbate and menadione causes cancer cell death by oxidative stress and replicative stress, Free Radic, Biol. Med, vol.134, pp.350-358, 2019.

G. P. Bienert, J. K. Schjoerring, and T. P. Jahn, Membrane transport of hydrogen peroxide, Biochim. Biophys. Acta, vol.1758, issue.8, pp.994-1003, 2006.

H. Tsukaguchi, T. Tokui, B. Mackenzie, U. V. Berger, X. Z. Chen et al., A family of mammalian Na+-dependent L-ascorbic acid transporters, Nature, vol.399, issue.6731, pp.70-75, 1999.

E. Pena, F. J. Roa, E. Inostroza, K. Sotomayor, M. Gonzalez et al., Increased expression of mitochondrial sodium-coupled ascorbic acid transporter-2 (mitSVCT2) as a central feature in breast cancer, Free Radic, Biol. Med, vol.135, pp.283-292, 2019.

J. C. Vera, C. I. Rivas, R. H. Zhang, C. M. Farber, and D. W. Golde, Human HL-60 myeloid leukemia cells transport dehydroascorbic acid via the glucose transporters and accumulate reduced ascorbic acid, Blood, vol.84, issue.5, pp.1628-1634, 1994.

J. M. May, Z. C. Qu, D. R. Neel, and X. Li, Recycling of vitamin C from its oxidized forms by human endothelial cells, Biochim. Biophys. Acta, vol.1640, issue.2-3, pp.153-161, 2003.

C. M. Stephenson, R. D. Levin, T. Spector, and C. G. Lis, Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer, Cancer Chemother. Pharmacol, vol.72, issue.1, pp.139-146, 2013.

L. J. Hoffer, M. Levine, S. Assouline, D. Melnychuk, S. J. Padayatty et al., Phase I clinical trial of i.v. ascorbic acid in advanced malignancy, Ann. Oncol, vol.19, issue.11, pp.1969-1974, 2008.

E. Banna, Biology, vol.26, p.101290, 2019.